{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:09:11Z","timestamp":1793696951622,"version":"4.5.1"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019345","name":"King Salman Center for Disability Research","doi-asserted-by":"publisher","award":["KSRG-2024-307"],"award-info":[{"award-number":["KSRG-2024-307"]}],"id":[{"id":"10.13039\/501100019345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.reth.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:17:14Z","timestamp":1755044234000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["CRISPR\/Cas9 a genomic engineering technology for treatment in ALS mouse models"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5096-7109","authenticated-orcid":false,"given":"Hamid","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubin Mustafa","family":"Kiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahibzada Muhammad","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shahab","family":"Ud Din Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"Abualait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz","family":"Al-hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib1","first-page":"5","article-title":"Amyotrophic lateral sclerosis, the primary motor neuron disease","volume":"1","author":"Naumann","year":"2015","journal-title":"The Downtown Review"},{"key":"10.1016\/j.reth.2025.07.009_bib2","first-page":"1","volume":"4","author":"Cwik","year":"2001"},{"issue":"7","key":"10.1016\/j.reth.2025.07.009_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4103\/1673-5374.272576","article-title":"Role of the NLRP3 inflammasome in neurodegenerative diseases and therapeutic implications","volume":"15","author":"Duan","year":"2020","journal-title":"Neural regeneration research"},{"key":"10.1016\/j.reth.2025.07.009_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2147\/IJN.S121956","article-title":"The antimicrobial activity of nanoparticles: present situation and prospects for the future","author":"Wang","year":"2017","journal-title":"Int J Nanomed"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13238-017-0397-3","article-title":"CRISPR\/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs","volume":"8","author":"Wang","year":"2017","journal-title":"Protein Cell"},{"issue":"33","key":"10.1016\/j.reth.2025.07.009_bib6","first-page":"5022","article-title":"Astrocytes pathology in ALS: a potential therapeutic target?","volume":"23","author":"Johann","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.reth.2025.07.009_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddmod.2018.10.001","article-title":"Modelling amyotrophic lateral sclerosis in mice","volume":"25","author":"Stephenson","year":"2017","journal-title":"Drug Discov Today Dis Model"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/ijms19030906","article-title":"CRISPR\/Cas9 technology as an emerging tool for targeting amyotrophic lateral sclerosis (ALS)","volume":"19","author":"Kruminis-Kaszkiel","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2025.07.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-015-0031-x","article-title":"CRISPR\/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases","volume":"10","author":"Tu","year":"2015","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","article-title":"CRISPR-Cas9-mediated gene therapy in neurological disorders","volume":"59","author":"Guan","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"12","key":"10.1016\/j.reth.2025.07.009_bib11","doi-asserted-by":"crossref","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0896-6273(00)81108-3","article-title":"From charcot to SOD1: mechanisms of selective motor neuron death in ALS","volume":"24","author":"Cleveland","year":"1999","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0960-8966(99)00071-1","article-title":"Amyotrophic lateral sclerosis: copper\/zinc superoxide dismutase (SOD1) gene mutations","volume":"10","author":"Orrell","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib14","first-page":"163","article-title":"New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes","volume":"1","author":"Kato","year":"2000","journal-title":"Amyotroph Lateral Scler"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1540-6210.2012.02678.x","article-title":"Designing public participation processes","volume":"73","author":"Bryson","year":"2013","journal-title":"Public Adm Rev"},{"key":"10.1016\/j.reth.2025.07.009_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00401-010-0646-5","article-title":"Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form","volume":"119","author":"Kerman","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.reth.2025.07.009_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11940-023-00757-4","article-title":"Update on ALS treatment","volume":"25","author":"Priyadarshini","year":"2023","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3934\/Neuroscience.2024010","article-title":"Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: a literature review","volume":"11","author":"Ansari","year":"2024","journal-title":"AIMS neuroscience"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42003-021-01942-4","article-title":"Efficacy and long-term safety of CRISPR\/Cas9 genome editing in the SOD1-linked mouse models of ALS","volume":"4","author":"Deng","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.reth.2025.07.009_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9086-3_1","article-title":"The applicability of mouse models to the study of human disease","author":"Rydell-T\u00f6rm\u00e4nen","year":"2019","journal-title":"Mouse Cell Cult Methods Protoc"},{"issue":"9","key":"10.1016\/j.reth.2025.07.009_bib21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ncb437","article-title":"The mouse ascending: perspectives for human-disease models","volume":"9","author":"Rosenthal","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.reth.2025.07.009_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.024","article-title":"Mouse models of ALS: past, present and future","volume":"1693","author":"Lutz","year":"2018","journal-title":"Brain Res"},{"issue":"7","key":"10.1016\/j.reth.2025.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00580-17","article-title":"History of CRISPR-cas from encounter with a mysterious repeated sequence to genome editing technology","volume":"200","author":"Ishino","year":"2018","journal-title":"J Bacteriol"},{"issue":"8","key":"10.1016\/j.reth.2025.07.009_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1134\/S0006297922080090","article-title":"CRISPR\u2013cas9: a history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya","year":"2022","journal-title":"Biochemistry (Mosc)"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.reth.2025.07.009_bib161","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12035-016-0335-z","article-title":"Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1 G93A ALS mouse model via upregulation of D-amino acid oxidase","volume":"55","author":"Lin","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib31","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1038\/s41467-020-18949-w","article-title":"Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS","volume":"11","author":"Kao","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib162","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/biology11020298","article-title":"Selective loss of MATR3 in spinal interneurons, upper motor neurons and hippocampal CA1 neurons in a MATR3 S85C knock-in mouse model of amyotrophic lateral sclerosis","volume":"11","author":"You","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.reth.2025.07.009_bib163","series-title":"Nuclear transport under stress: direct and indirect effects of polyPR and polyGA derail nuclear transport in C9Orf72 yeast models","author":"Semmelink","year":"2022"},{"key":"10.1016\/j.reth.2025.07.009_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-019-0685-7","article-title":"C9orf72 deficiency promotes motor deficits of a C9ALS\/FTD mouse model in a dose-dependent manner","volume":"7","author":"Shao","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neuron.2020.03.005","article-title":"The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice","volume":"106","author":"Gerbino","year":"2020","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib166","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20180729","article-title":"Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice","volume":"216","author":"Brenner","year":"2019","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib167","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41593-018-0113-5","article-title":"TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD","volume":"21","author":"White","year":"2018","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib168","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40478-025-01962-9","article-title":"Endogenous TDP-43 mislocalization in a novel knock-in mouse model reveals DNA repair impairment, inflammation, and neuronal senescence","volume":"13","author":"Mitra","year":"2025","journal-title":"Acta Neuropathologica Communications"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib169","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/19768354.2024.2322054","article-title":"Factors affecting the cleavage efficiency of the CRISPR-Cas9 system","volume":"28","author":"Jung","year":"2024","journal-title":"Anim Cell Syst"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib170","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/brain\/awaa079","article-title":"Predicting incidences of neurodevelopmental disorders","volume":"143","author":"Lemke","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib171","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","article-title":"In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.reth.2025.07.009_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00294-019-01040-3","article-title":"A glance at genome editing with CRISPR\u2013Cas9 technology","volume":"66","author":"Barman","year":"2020","journal-title":"Curr Genet"},{"key":"10.1016\/j.reth.2025.07.009_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","article-title":"CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer's disease","volume":"11","author":"Gy\u00f6rgy","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib28","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-020-17725-0","article-title":"Engineering designer beta cells with a CRISPR-Cas9 conjugation platform","volume":"11","author":"Lim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.reth.2025.07.009_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbrc.2021.06.052","article-title":"MATR3 F115C knock-in mice do not exhibit motor defects or neuropathological features of ALS","volume":"568","author":"van Bruggen","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.reth.2025.07.009_bib30","series-title":"Characterization of FAMILIAL MATRIN 3 S85C and F115C mutations in ALS","author":"Kim","year":"2019"},{"key":"10.1016\/j.reth.2025.07.009_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fenvs.2021.763917","article-title":"Indirect effects of the herbicide glyphosate on plant, animal and human health through its effects on microbial communities","volume":"9","author":"Van Bruggen","year":"2021","journal-title":"Front Environ Sci"},{"issue":"10","key":"10.1016\/j.reth.2025.07.009_bib33","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/acn3.51194","article-title":"Promoting identification of amyotrophic lateral sclerosis based on label\u2010free plasma spectroscopy","volume":"7","author":"Zhang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/brain\/awaa076","article-title":"In vivo stress granule misprocessing evidenced in a FUS knock-in ALS mouse model","volume":"143","author":"Zhang","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10465","article-title":"ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function","volume":"7","author":"Sharma","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.reth.2025.07.009_bib36","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1007\/s11064-020-03137-5","article-title":"ALS-linked mutant SOD1 associates with TIA-1 and alters stress granule dynamics","volume":"45","author":"Lee","year":"2020","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.celrep.2017.12.036","article-title":"TIA-1 self-multimerization, phase separation, and recruitment into stress granules are dynamically regulated by Zn2+","volume":"22","author":"Rayman","year":"2018","journal-title":"Cell Rep"},{"issue":"21","key":"10.1016\/j.reth.2025.07.009_bib38","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1093\/hmg\/ddq335","article-title":"Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules","volume":"19","author":"Bosco","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.reth.2025.07.009_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-8-30","article-title":"Amyotrophic lateral sclerosis-linked FUS\/TLS alters stress granule assembly and dynamics","volume":"8","author":"Baron","year":"2013","journal-title":"Mol Neurodegener"},{"issue":"11","key":"10.1016\/j.reth.2025.07.009_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004763","article-title":"Stress granule-defective mutants deregulate stress responsive transcripts","volume":"10","author":"Yang","year":"2014","journal-title":"PLoS Genet"},{"issue":"11","key":"10.1016\/j.reth.2025.07.009_bib41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41583-019-0222-5","article-title":"Stress granules and neurodegeneration","volume":"20","author":"Wolozin","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.reth.2025.07.009_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.604171","article-title":"Human motor neurons with SOD1-G93A mutation generated from CRISPR\/Cas9 gene-edited iPSCs develop pathological features of amyotrophic lateral sclerosis","volume":"14","author":"Kim","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/brb3.143","article-title":"Characterization of early pathogenesis in the SOD1 G93A mouse model of ALS: part I, background and methods","volume":"3","author":"Vinsant","year":"2013","journal-title":"Brain Behavior"},{"issue":"11\u201312","key":"10.1016\/j.reth.2025.07.009_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1089\/ars.2006.8.2075","article-title":"On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis","volume":"8","author":"Hensley","year":"2006","journal-title":"Antioxidants Redox Signal"},{"issue":"15","key":"10.1016\/j.reth.2025.07.009_bib45","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.3390\/ijms22158194","article-title":"Progressive mitochondrial SOD1G93A accumulation causes severe structural, metabolic and functional aberrations through OPA1 down-regulation in a mouse model of amyotrophic lateral sclerosis","volume":"22","author":"M\u00e9ndez-L\u00f3pez","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109166","article-title":"Homozygous ALS-linked mutations in TARDBP\/TDP-43 lead to hypoactivity and synaptic abnormalities in human iPSC-derived motor neurons","volume":"27","author":"L\u00e9pine","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.reth.2025.07.009_bib47","series-title":"Mechanism and genetic susceptibility of neurological disorders","first-page":"199","article-title":"Axonal degeneration, impaired axonal transport, and synaptic dysfunction in motor neuron disorder","author":"Parveen","year":"2024"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/brain\/118.4.971","article-title":"Motor neuron disease: studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation","volume":"118","author":"Mills","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.reth.2025.07.009_bib49","series-title":"Optimizing CRISPR\/Cas9 for gene silencing of SOD1 in mouse models of ALS","author":"Kennedy","year":"2019"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib50","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2010.06683.x","article-title":"Intracerebroventricular infusion of monoclonal antibody or its derived fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS","volume":"113","author":"Gros\u2010Louis","year":"2010","journal-title":"J Neurochem"},{"issue":"23","key":"10.1016\/j.reth.2025.07.009_bib51","doi-asserted-by":"crossref","first-page":"15845","DOI":"10.1074\/jbc.M800834200","article-title":"Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression\u2217\u2666","volume":"283","author":"Wang","year":"2008","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.reth.2025.07.009_bib52","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.24618","article-title":"Adeno\u2010associated virus\u2013delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model","volume":"79","author":"Stoica","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","article-title":"Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)","volume":"24","author":"Abati","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12967-024-05661-2","article-title":"Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside","volume":"22","author":"Xu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2025.07.009_bib57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fncel.2015.00336","article-title":"SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis","volume":"9","author":"Tafuri","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2015.11.049","article-title":"Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis","volume":"577","author":"Kaur","year":"2016","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00401-010-0646-5","article-title":"Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form","volume":"119","author":"Kerman","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib60","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12035-016-0335-z","article-title":"Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1G93A ALS mouse model via upregulation of D-amino acid oxidase","volume":"55","author":"Lin","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib61","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41598-018-23607-9","article-title":"Systemic IGF-1 gene delivery by rAAV9 improves spontaneous autoimmune peripheral polyneuropathy (SAPP)","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/ars.1999.1.2-129","article-title":"Activation of NF-\u03ba B by reactive oxygen intermediates in the nervous system","volume":"1","author":"Kaltschmidt","year":"1999","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.reth.2025.07.009_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105484","article-title":"The effect of IGFBP3 gene knockout by the CRISPR\/Cas9 system on the IGF-1 pathway in murine cells","volume":"125","author":"Eom","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.reth.2025.07.009_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2018.02.004","article-title":"Intrathecal injection of scAAV9\u2013hIGF1 prolongs the survival of ALS model mice by inhibiting the NF-kB pathway","volume":"381","author":"Hu","year":"2018","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.reth.2025.07.009_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-5793(02)02860-0","article-title":"RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells","volume":"521","author":"Hohjoh","year":"2002","journal-title":"FEBS Lett"},{"issue":"39","key":"10.1016\/j.reth.2025.07.009_bib66","doi-asserted-by":"crossref","first-page":"E8294","DOI":"10.1073\/pnas.1704294114","article-title":"Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS","volume":"114","author":"Rudnick","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1207","article-title":"Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS","volume":"11","author":"Raoul","year":"2005","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib68","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1074\/jbc.RA118.006496","article-title":"Optimizing CRISPR\/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice","volume":"294","author":"Miao","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.reth.2025.07.009_bib69","series-title":"Investigating how the ALS-linked S85C mutation in Matrin-3 causes neurodegeneration","author":"Maksimovi\u0107","year":"2022"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18949-w","article-title":"Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS","volume":"11","author":"Kao","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.reth.2025.07.009_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fnmol.2017.00035","article-title":"The role of dipeptide repeats in C9ORF72-related ALS-FTD","volume":"10","author":"Freibaum","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.reth.2025.07.009_bib72","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS genetics, mechanisms, and therapeutics: where are we now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","article-title":"Rapid single-step induction of functional neurons from human pluripotent stem cells","volume":"78","author":"Zhang","year":"2013","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.reth.2025.07.009_bib74","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/ijms21113801","article-title":"CRISPR\/Cas9-mediated gene correction to understand ALS","volume":"21","author":"Yun","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib75","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100989","article-title":"Abnormal TDP\u201043 function impairs activity\u2010dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing","volume":"38","author":"Tann","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.reth.2025.07.009_bib76","series-title":"TDP-43 and NOVA-1 RNA binding proteins as splicing regulators of tnik gene, a schizophrenia genetic risk factor","author":"Gumina","year":"2019"},{"key":"10.1016\/j.reth.2025.07.009_bib77","series-title":"Splicing regulatory role of RNA binding proteins in suppressing the toxic Ex17b inclusion in human Sort1 mRNA","author":"Mohagheghi","year":"2017"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415598290","article-title":"SORT1 mutation resulting in sortilin deficiency and p75NTR upregulation in a family with essential tremor","volume":"7","author":"S\u00e1nchez","year":"2015","journal-title":"ASN neuro"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ame2.12129","article-title":"Knock in of a hexanucleotide repeat expansion in the C9orf72 gene induces ALS in rats","volume":"3","author":"Dong","year":"2020","journal-title":"Anim Models Exp Med"},{"key":"10.1016\/j.reth.2025.07.009_bib80","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1186\/1744-8069-7-9","article-title":"Identification and characterization of seven new exon 11-associated splice variants of the rat mu opioid receptor gene, OPRM1","volume":"7","author":"Xu","year":"2011","journal-title":"Mol Pain"},{"key":"10.1016\/j.reth.2025.07.009_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0274-4","article-title":"Long-read sequencing across the C9orf72 \u2018GGGGCC\u2019repeat expansion: implications for clinical use and genetic discovery efforts in human disease","volume":"13","author":"Ebbert","year":"2018","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13024-022-00525-z","article-title":"The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS\/FTD","volume":"17","author":"Masrori","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.reth.2025.07.009_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01039-z","article-title":"BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS\/FTD model","volume":"13","author":"Quezada","year":"2021","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.reth.2025.07.009_bib84","volume":"9","author":"Gittings","year":"2020"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib85","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/febs.15501","article-title":"Ablation of C9orf72 together with excitotoxicity induces ALS in rats","volume":"288","author":"Dong","year":"2021","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib86","article-title":"Applications of the versatile CRISPR\u2010Cas13 RNA targeting system","volume":"13","author":"Kordy\u015b","year":"2022","journal-title":"Wiley Interdisciplinary Reviews: RNA"},{"issue":"19","key":"10.1016\/j.reth.2025.07.009_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911400","article-title":"Insights gained from RNA editing targeted by the CRISPR-Cas13 family","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"9\u201310","key":"10.1016\/j.reth.2025.07.009_bib89","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/hum.2019.264","article-title":"High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction","volume":"31","author":"Westhaus","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib90","doi-asserted-by":"crossref","first-page":"eabk2485","DOI":"10.1126\/sciadv.abk2485","article-title":"Targeted gene silencing in the nervous system with CRISPR-Cas13","volume":"8","author":"Powell","year":"2022","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.reth.2025.07.009_bib92","series-title":"RNA interference and CRISPR technologies","author":"Sioud","year":"2020"},{"key":"10.1016\/j.reth.2025.07.009_bib93","first-page":"23","article-title":"Chemical modifications in RNA interference and CRISPR\/Cas genome editing reagents","author":"Lennox","year":"2020","journal-title":"RNA Interf CRISPR Technol Tech Adv New Ther Oppor"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib94","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1093\/nar\/gkab1207","article-title":"Identification and classification of reverse transcriptases in bacterial genomes and metagenomes","volume":"50","author":"Sharifi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.reth.2025.07.009_bib95","series-title":"Smart technologies for sustainable development goals: zero hunger","article-title":"12| innovative technologies for alleviating","author":"Farhat","year":"2025"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib96","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molcel.2015.10.030","article-title":"Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes","volume":"60","author":"Ma","year":"2015","journal-title":"Mol Cell"},{"issue":"6213","key":"10.1016\/j.reth.2025.07.009_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"7675","key":"10.1016\/j.reth.2025.07.009_bib98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.reth.2025.07.009_bib99","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.reth.2025.07.009_bib100","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/Cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Accounts Chem Res"},{"key":"10.1016\/j.reth.2025.07.009_bib101","first-page":"33","article-title":"The CRISPR-Cas9 tool of gene editing: cheaper, faster, riskier","volume":"26","author":"Furrow","year":"2017","journal-title":"Ann Health Law"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib102","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40005-024-00669-8","article-title":"Oligonucleotide therapeutics and their chemical modification strategies for clinical applications","volume":"54","author":"Kim","year":"2024","journal-title":"Journal of Pharmaceutical Investigation"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib103","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib104","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1039\/D1CB00038A","article-title":"Sulfur modification in natural RNA and therapeutic oligonucleotides","volume":"2","author":"Zheng","year":"2021","journal-title":"RSC Chem Biol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib105","first-page":"25","article-title":"RNA modifications in mammals: from basic research to biotechnological application","volume":"7","author":"Li","year":"2025","journal-title":"ExRNA"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib106","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"10.1016\/j.reth.2025.07.009_bib107","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib109","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4103\/1673-5374.385285","article-title":"Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases","volume":"19","author":"Romano","year":"2024","journal-title":"Neural Regeneration Research"},{"issue":"22","key":"10.1016\/j.reth.2025.07.009_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2025.07.009_bib111","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/S0033583519000052","article-title":"Development of CRISPR-Cas systems for genome editing and beyond","volume":"52","author":"Zhang","year":"2019","journal-title":"Q Rev Biophys"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17482960701262376","article-title":"Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence\u2010based review with good practice points. EALSC working group","volume":"8","author":"Andersen","year":"2007","journal-title":"Amyotroph Lateral Scler"},{"issue":"11","key":"10.1016\/j.reth.2025.07.009_bib113","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"15","key":"10.1016\/j.reth.2025.07.009_bib114","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.3390\/ijms23158714","article-title":"Applications of CRISPR-Cas9 in alzheimer's disease and related disorders","volume":"23","author":"De Plano","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.reth.2025.07.009_bib115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10529-018-2555-y","article-title":"Therapeutic applications of CRISPR\/Cas9 system in gene therapy","volume":"40","author":"Mollanoori","year":"2018","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.reth.2025.07.009_bib116","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pnpbp.2017.04.003","article-title":"Use of CRISPR\/Cas9 to model brain diseases","volume":"81","author":"Yan","year":"2018","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatr"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-015-0031-x","article-title":"CRISPR\/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases","volume":"10","author":"Tu","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.reth.2025.07.009_bib118","volume":"6","author":"Lau","year":"2017"},{"issue":"6","key":"10.1016\/j.reth.2025.07.009_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902312","article-title":"CRISPR\/cas systems in genome editing: methodologies and tools for sgRNA design, off\u2010target evaluation, and strategies to mitigate off\u2010target effects","volume":"7","author":"Manghwar","year":"2020","journal-title":"Adv Sci"},{"key":"10.1016\/j.reth.2025.07.009_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.reth.2025.07.009_bib121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-90-481-3471-7_14","article-title":"Nonhomologous DNA end joining (NHEJ) and chromosomal translocations in humans","author":"Lieber","year":"2010","journal-title":"Genome Stability Human Diseases"},{"key":"10.1016\/j.reth.2025.07.009_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-015-2284-8","article-title":"Genome editing through large insertion leads to the skipping of targeted exon","volume":"16","author":"Uddin","year":"2015","journal-title":"BMC Genom"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib123","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pneurobio.2008.01.001","article-title":"Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS","volume":"85","author":"Turner","year":"2008","journal-title":"Prog Neurobiol"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib124","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bpa.12351","article-title":"New insights on the mechanisms of disease course variability in ALS from mutant SOD1 mouse models","volume":"26","author":"Nardo","year":"2016","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib126","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/15476286.2019.1582974","article-title":"CRISPR-cas in Streptococcus pyogenes","volume":"16","author":"Le Rhun","year":"2019","journal-title":"RNA Biol"},{"key":"10.1016\/j.reth.2025.07.009_bib127","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.omtm.2019.02.008","article-title":"Advancements and obstacles of CRISPR-Cas9 technology in translational research","volume":"13","author":"You","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.reth.2025.07.009_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0732-2","article-title":"Immune response in peripheral axons delays disease progression in SOD1 G93A mice","volume":"13","author":"Nardo","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.reth.2025.07.009_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0271-7","article-title":"Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1 G93A mice","volume":"13","author":"Nardo","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.reth.2025.07.009_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575792","article-title":"Very early involvement of innate immunity in peripheral nerve degeneration in SOD1-G93A mice","volume":"11","author":"Angelini","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","article-title":"Novel genome-editing-based approaches to treat motor neuron diseases: promises and challenges","volume":"30","author":"Miccio","year":"2022","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib132","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4103\/1673-5374.206635","article-title":"Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease","volume":"12","author":"Jaiswal","year":"2017","journal-title":"Neural regeneration research"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib133","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/biology12020186","article-title":"AAV engineering for improving tropism to the central nervous system","volume":"12","author":"Ghauri","year":"2023","journal-title":"Biology"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib134","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/gt.2017.18","article-title":"Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders","volume":"24","author":"Bey","year":"2017","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/ijms24021130","article-title":"Gene therapy in ALS and SMA: advances, challenges and perspectives","volume":"24","author":"Lejman","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.reth.2025.07.009_bib136","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10529-018-2555-y","article-title":"Therapeutic applications of CRISPR\/Cas9 system in gene therapy","volume":"40","author":"Mollanoori","year":"2018","journal-title":"Biotechnol Lett"},{"issue":"5","key":"10.1016\/j.reth.2025.07.009_bib137","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s12640-022-00564-w","article-title":"CRISPR and iPSCs: recent developments and future perspectives in neurodegenerative disease modelling, research, and therapeutics","volume":"40","author":"Sen","year":"2022","journal-title":"Neurotox Res"},{"key":"10.1016\/j.reth.2025.07.009_bib138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fpubh.2017.00117","article-title":"A CRISPR new world: attitudes in the public toward innovations in human genetic modification","volume":"5","author":"Weisberg","year":"2017","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.reth.2025.07.009_bib139","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40120-023-00548-8","article-title":"Roadmap for C9ORF72 in frontotemporal dementia and amyotrophic lateral sclerosis: report on the C9ORF72 FTD\/ALS summit","volume":"12","author":"Sattler","year":"2023","journal-title":"Neurology Therapy"},{"key":"10.1016\/j.reth.2025.07.009_bib140","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1007\/s12035-016-9993-0","article-title":"Development of therapeutics for C9ORF72 ALS\/FTD-related disorders","volume":"54","author":"Mis","year":"2017","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12987-024-00565-1","article-title":"A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery","volume":"21","author":"Wasielewska","year":"2024","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib142","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/1389557521666210913112030","article-title":"CRISPR-Cas9 genome engineering: trends in medicine and health","volume":"22","author":"Zaib","year":"2022","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib143","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-0173(98)00049-6","article-title":"Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration","volume":"29","author":"Morrison","year":"1999","journal-title":"Brain Res Rev"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib144","doi-asserted-by":"crossref","DOI":"10.1080\/2331205X.2019.1582400","article-title":"Genetic alterations of C9orf72, SOD1, TARDBP, FUS, and UBQLN2 genes in patients with amyotrophic lateral sclerosis","volume":"6","author":"Vildan","year":"2019","journal-title":"Cogent Medicine"},{"issue":"8","key":"10.1016\/j.reth.2025.07.009_bib145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jmg.2010.077180","article-title":"SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype\u2013phenotype correlations","volume":"47","author":"Millecamps","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.reth.2025.07.009_bib146","series-title":"Optimizing CRISPR\/Cas9 for gene silencing of SOD1 in mouse models of ALS","author":"Kennedy","year":"2019"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib147","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/pbi.12771","article-title":"Increasing the efficiency of CRISPR\u2010Cas9\u2010VQR precise genome editing in rice","volume":"16","author":"Hu","year":"2018","journal-title":"Plant Biotechnol J"},{"issue":"8","key":"10.1016\/j.reth.2025.07.009_bib148","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/pbi.13383","article-title":"Genome editing with the CRISPR\u2010Cas system: an art, ethics and global regulatory perspective","volume":"18","author":"Zhang","year":"2020","journal-title":"Plant Biotechnol J"},{"issue":"4","key":"10.1016\/j.reth.2025.07.009_bib149","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s43016-020-0051-8","article-title":"A CRISPR way for accelerating improvement of food crops","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Food"},{"key":"10.1016\/j.reth.2025.07.009_bib150","series-title":"Characterization of Matrin-3 mutations associated with amyotrophic lateral sclerosis","author":"Kao","year":"2020"},{"key":"10.1016\/j.reth.2025.07.009_bib151","series-title":"Nucleic acid biology and its application in human diseases","first-page":"105","article-title":"Nucleic acid-based strategies to treat neurodegenerative diseases","author":"Panda","year":"2023"},{"issue":"6","key":"10.1016\/j.reth.2025.07.009_bib152","first-page":"707","article-title":"Oligonucleotide therapeutics in neurodegenerative diseases","volume":"15","author":"Scoles","year":"2018","journal-title":"RNA Biol"},{"issue":"2","key":"10.1016\/j.reth.2025.07.009_bib153","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bph.16424","article-title":"Discovery platforms for RNA therapeutics","volume":"182","author":"Ciucci","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.reth.2025.07.009_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102195","article-title":"RNA therapeutics in targeting G protein-coupled receptors: recent advances and challenges","author":"Yuan","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.reth.2025.07.009_bib155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.gene.2018.10.072","article-title":"CRISPR\/cas system: a game changing genome editing technology, to treat human genetic diseases","volume":"685","author":"Hussain","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.reth.2025.07.009_bib156","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.copbio.2014.11.007","article-title":"Editing plant genomes with CRISPR\/Cas9","volume":"32","author":"Belhaj","year":"2015","journal-title":"Curr Opin Biotechnol"},{"issue":"1\u20132","key":"10.1016\/j.reth.2025.07.009_bib157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neurol.2022.10.001","article-title":"Therapeutic tools for familial ALS","volume":"179","author":"Camu","year":"2023","journal-title":"Rev Neurol"},{"issue":"3","key":"10.1016\/j.reth.2025.07.009_bib158","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamaneurol.2023.4983","article-title":"Building CRISPR gene therapies for the central nervous system: a review","volume":"81","author":"Salomonsson","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.reth.2025.07.009_bib159","first-page":"45","article-title":"The development of new treatments for neurological disorders: insights, innovations, and ethical foundations","volume":"1","author":"Uyyala","year":"2023","journal-title":"IJMHS"},{"key":"10.1016\/j.reth.2025.07.009_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.644319","article-title":"Delivery platforms for CRISPR\/Cas9 genome editing of glial cells in the central nervous system","volume":"3","author":"Meneghini","year":"2021","journal-title":"Frontiers in Genome Editing"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425001634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425001634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:25:29Z","timestamp":1764692729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320425001634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":171,"alternative-id":["S2352320425001634"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2025.07.009","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9 a genomic engineering technology for treatment in ALS mouse models","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}]}}